| Catalog No. | HB796016 |
| Host species | Human |
| Species reactivity | Human |
| Form | Liquid |
| Storage buffer | 0.01M PBS, pH 7.4. |
| Purity | >95% purity as determined by SDS-PAGE. |
| Clonality | Monoclonal |
| Isotype | IgG1-kappa |
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| Target | CD27L receptor, TNFRSF7, T14, CD27 antigen, Tumor necrosis factor receptor superfamily member 7, CD27, T-cell activation antigen CD27 |
| Purification | Protein A/G purified from cell culture supernatant. |
| Endotoxin level | Please contact the lab for this information. |
| Expression system | Mammalian Cells |
| Accession | P26842 |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternative name | 1F5, CDX-1127, 1393344-72-3 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
Research Grade Varlilumab
Overview
Description
Varlilumab is a fully human monoclonal antibody (mAb) that targets CD27, a critical molecule in the activation pathway of lymphocytes. Like CD40, CD27 can be effectively manipulated with activating antibodies to induce potent anti-tumor responses, and may result in less toxicities due to its restricted expression and regulation. Varlilumab is a novel, first-in-class, agonist CD27 antibody that stimulates the CD27 pathway, which results in T-cell activation and anti-tumor activity in tumor models. This first-in-human, dose-escalation and expansion study evaluated the safety, pharmacology, and activity of varlilumab in patients with advanced solid tumors.
Images
 SDS-PAGE |
SDS-PAGE for Research Grade Varlilumab. |